Oncocyte raises ~$13.5M in offering of 45.5M shares at $0.302-$0.354

Insight Molecular Diagnostics Inc.

Net proceeds of ~$13.5M after $250K advisory fee and other expenses.
~$1.1M used to redeem Series A Preferred stock; remainder for working capital and product commercialization.
Broadwood Partners (largest shareholder) and board members participated as insiders at $0.35440 per share.
Offering conducted as takedown from existing S-3 shelf registration statement declared effective June 2021.
Company intends to use funds to support VitaGraft, DetermaIO, and DetermaCNI development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.